spacer
home > ebr > winter 2019 > embracing a new lease of life
PUBLICATIONS
European Biopharmaceutical Review

Embracing a New Lease of Life

EBR:What are the advantages of drug repurposing in comparison to developing a new drug?

Alex Kiselyov: There are notable advantages of drug repurposing which include the understanding of molecular target, pathway, or network pharmacology, as well as a chance to identify agents that ‘make sense’ from the point of view of signalling mechanisms involved in the disease pathology. It can also provide an insight into molecular biophysics, lead-like properties as exemplified by solubility, lipophilicity, plasma protein binding, and metabolic stability.

There is opportunity for a rapid analoging based on either chemotype, biological profile (fingerprint), or both. If desired, potential to establish new intellectual property (IP) is possible via medicinal chemistry or a structurebased drug discovery route using known or suspected molecular targets for the molecule. For pharmaceutical companies with a large compound collection (library), there is a chance to select target-based or structurebased ‘similars’ with clear IP. Furthermore, another advantage is a frequently detailed understanding of in vivo and clinical (human) safety, dosing regimens, pharmacokinetics (PK), and pharmacodynamics (PD), including specific target engagement in a tissue of relevance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alex Kiselyov, at Genea Biocells, has over 20 years of industry experience in drug discovery and development. He has contributed to multiple clinical programmes encompassing oncology, cardiovascular disease, dementias and cognitive disorders, and spinal muscular atrophy. His latest endeavour included identification of the targeted treatment for facioscapulohumeral dystrophy that received orphan drug designation in May 2018. Alex has contributed to over 170 papers and seven book chapters and has 50 awarded patents and patent applications.
spacer
Alex Kiselyov
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biotechpharma to Expand Process Development and GMP Manufacturing Capacity to 5,000L

Biotechpharma UAB, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced further expansion of its fermentation capacity to 5,000L along with an additional state of the art process development laboratory, investing more than €50 million in the expansion.
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement